Insider · CIK 0001378166
David Young
Files at PCSA (Processa Pharmaceuticals, Inc.). First filing Apr 1, 2026, latest Jul 1, 2026.
In brief
David Young files SEC Form 4 as officer, director and 10% owner at PCSA (Processa Pharmaceuticals, Inc.). Since Apr 1, 2026, David Young has reported 7 open-market buys worth $32k and 0 open-market sells worth $0, the latest filed on Jul 1, 2026.
A track record needs three past buys with six months of prices behind them; David Young has 0, so none is measured yet.
The newest scored trade: bought $4,885 of PCSA on Jun 30, 2026, filed Jul 1, 2026, scored 56 (moderate). In the last 12 months: 7 buys worth $32k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PCSA: Processa Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Processa Pharmaceuticals, Inc. | $4,885 2,531 shares | +13% | +4% from low-84% from high | |
| 46Moderate | Processa Pharmaceuticals, Inc. | $4,589 2,067 shares | +12% | +19% from low-82% from high | |
| 46Moderate | Processa Pharmaceuticals, Inc. | $4,590 1,786 shares | +12% | +38% from low-79% from high | |
| 46Moderate | Processa Pharmaceuticals, Inc. | $4,589 1,545 shares | +11% | +60% from low-75% from high | |
| 46Moderate | Processa Pharmaceuticals, Inc. | $4,589 1,706 shares | +14% | +46% from low-77% from high | |
| 46Moderate | Processa Pharmaceuticals, Inc. | $4,589 1,545 shares | +15% | +60% from low-75% from high | |
| 44Moderate | Processa Pharmaceuticals, Inc. | $4,588 1,810 shares | +21% | +36% from low-79% from high |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,531 | $1.93 | $4,885 | 21,729 | Jul 1, 2026 |
| Jun 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,067 | $2.22 | $4,589 | 19,198 | Jun 16, 2026 |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,786 | $2.57 | $4,590 | 17,131 | Jun 1, 2026 |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,545 | $2.97 | $4,589 | 15,345 | May 19, 2026 |
| Apr 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,706 | $2.69 | $4,589 | 13,813 | May 1, 2026 |
| Apr 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,545 | $2.97 | $4,589 | 12,107 | Apr 17, 2026 |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,810 | $2.54 | $4,588 | 10,562 | Apr 1, 2026 |
| Jan 1, 2026 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Common Stock | +49 | $0.00 | $0 | 8,752 | Feb 4, 2026 |
| Jan 1, 2026 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -49 | $0.00 | $0 | 0 | Feb 4, 2026 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +111,000 | $0.00 | $0 | 111,000 | Oct 3, 2025 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +333,000 | $0.00 | $0 | 333,000 | Oct 3, 2025 |
| Jul 24, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +1,813,133 | $0.00 | $0 | 1,821,016 | Jul 28, 2025 |
| Apr 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | MOption exercise Common Stock | +17,272 | - | - | 222,677 | Apr 11, 2025 |
| Apr 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | FTax withholding Common Stock | -5,345 | $0.41 | $2,202 | 217,332 | Apr 11, 2025 |
| Oct 12, 2023 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Common Stock | +155,277 | $0.29 | $45k | 767,701 | Oct 12, 2023 |
Questions about David Young
Answered from the filings on this page, as of the latest one.
Is David Young buying or selling?
In the last 12 months David Young reported 7 open-market buys worth $32k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $4,885 of PCSA on Jun 30, 2026. Grants, option exercises and tax withholding are not counted.
How did David Young's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Young has 0.
Where does David Young file Form 4?
David Young has filed Form 4 at PCSA (Processa Pharmaceuticals, Inc.) as Pres. Research & Development. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.